StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
3
Publishing Date
2022 - 06 - 24
1
2022 - 02 - 28
2
Sector
Health technology
3
Tags
Active
10
Agreement
8
Ajovy
8
Alzheimer's
9
America
38
Application
11
Approval
13
Asia
13
Austedo
9
Avt02
11
Avt04
11
Biosimilar
41
Business
12
Cancer
21
Children
18
Clinical-trials-phase-iii
8
Collaboration
9
Conference
20
Dermatitis
8
Disease
36
Drug
44
Dupixent
34
Earnings
14
Europe
15
Events
10
Expected
12
Fda
22
Financial
21
Global
111
Growing
17
Growth
133
Health
11
Libtayo
8
License
11
Liver
8
Market
313
Migraine
9
N/a
514
Pharm-country
18
Pharma
11
Pharmaceuticals
9
Phase 3
15
Positive
14
Reach
16
Report
95
Research
59
Respiratory
10
Results
47
Review
8
Set
12
Stelara
12
Study
20
System
11
Teva
53
Therapeutics
64
Therapy
14
Treatment
76
Trial
12
Update
20
Year
8
Entities
Intellia therapeutics, inc.
3
Regeneron pharmaceuticals, inc.
3
Sanofi
3
Teva pharmaceutical industries ltd
3
Symbols
ABMD
14
AGEN
19
AKBA
27
ALDX
19
ALNY
37
AMLX
23
ATXS
13
AVRO
15
AXLA
14
BFRI
14
BGNE
15
BIIB
24
BLUE
20
BPMC
19
BRKR
17
BSX
16
CDAK
12
CRL
36
CVAC
18
CYT
13
DCPH
26
ENTA
19
ENVB
19
EYPT
12
FHTX
16
FNCTF
26
GILD
12
HOLX
14
IMGN
20
INFI
14
ISPC
15
JNJ
31
KRTX
19
KYMR
14
LLY
17
MASS
13
MCRB
32
MRNA
68
MS
27
OCUL
14
OMGA
12
PBIO
18
PKI
33
QTRX
22
RNAZ
14
RUBY
13
SLDB
12
SNY
73
SNYNF
59
SQZ
12
SRPT
22
SRRK
16
SYRS
20
TAK
22
TMO
28
TSVT
16
TTOO
14
VBIV
16
VRTX
27
VSTM
16
Exchanges
Nasdaq
3
Crawled Date
2022 - 06 - 24
1
2022 - 02 - 28
2
Crawled Time
12:00
1
23:00
2
Source
www.biospace.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Genetown
symbols :
TEVJF
save search
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
Published:
2022-06-24
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.19%
|
O:
8.01%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-10.17%
|
O:
3.49%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
48.37%
|
O:
0.77%
H:
0.18%
C:
0.07%
NTLA
|
$21.57
1.17%
1.16%
1.4M
|
Health Technology
|
-58.0%
|
O:
3.45%
H:
5.18%
C:
1.71%
ntla-2001
treatment
phase 1
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published:
2022-02-28
(Crawled : 23:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-13.07%
|
O:
-0.49%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
45.67%
|
O:
-1.15%
H:
1.44%
C:
1.12%
NTLA
|
$21.57
1.17%
1.16%
1.4M
|
Health Technology
|
-77.87%
|
O:
0.66%
H:
0.0%
C:
0.0%
ntla-2001
crispr
disease
intel
phase 1
therapy
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published:
2022-02-28
(Crawled : 23:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-13.07%
|
O:
-0.49%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
45.67%
|
O:
-1.15%
H:
1.44%
C:
1.12%
NTLA
|
$21.57
1.17%
1.16%
1.4M
|
Health Technology
|
-77.87%
|
O:
0.66%
H:
0.0%
C:
0.0%
ntla-2001
crispr
disease
intel
phase 1
therapy
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.